Astex Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 5 of about 5   

Articles published

ASTX 0.0000
price chart
Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen(R) from ...
Dacogen(R) was developed by SuperGen, Inc., (now Astex Pharmaceuticals, Inc.) as a therapeutic agent for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) possessing cell differentiation-inducing activity through the inhibition of DNA ...
Related articles »  
Scientists Reduce Solar Panel Glare, Increase Efficiency
The work was funded by the Engineering and Physical Sciences (EPSRC) Supergen SuperSolar Hub. Tags:Loughborough Universityphotovoltaicsolar energy.
Loughborough University scientists develop anti-reflection coating for PV panels  Renewable Energy Magazine (press release)
Related articles »  
Inexpensive Coating Cuts Glare, Boosts Efficiency in Solar Panels
... operates in a different wavelength range and it is relatively simple to accommodate this in the multilayer design for each case,� Kaminski said.
Anti-Glare Spectacle Technology Applied To Solar Panels  Energy Matters
Related articles »  
Otsuka gets Eisai's Dacogen rights in US, Canada & Japan
Eisai Inc., a subsidiary of Tokyo-based Eisai Co. Ltd, announced the sale and ... enzyme inhibitor E7727 to Otsuka. Eisai's marketing rights for Dacogen flow from a worldwide license from Astex Pharmaceuticals,which was acquired by Otsuka in October 2013.
Related articles »  
Otsuka Acquires Leukemia Drug Dacogen� From Eisai
AsianScientist (Apr. 2, 2014) - Otsuka Pharmaceutical Co., Ltd. has acquired the rights to the hematological cancer treatment Dacogen� and an enzyme inhibitor E7727, from Eisai Inc., a subsidiary of Eisai Co., Ltd. Dacogen� is a DNA ... Otsuka will ...